Last reviewed · How we verify
NCT02334969
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM
Phase 4 trial testing Naoxintong Capsule in Ischemic Stroke in 2,200 participants. Completed in 30 August 2018.
30 August 2018
Quick facts
| Lead sponsor | Xiaofei Yu |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 2,200 |
| Start date | 1 April 2016 |
| Primary completion | 30 August 2018 |
| Estimated completion | 30 August 2018 |
| Sites | 24 locations across China |
Drugs / interventions tested
- Naoxintong Capsule — full drug profile →
- Placebo
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
Sponsor
Xiaofei Yu
Who can join
Adults 18 to 90, any sex, with Ischemic Stroke. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Stroke recurrence rate and Stroke mortality
Time frame: 2 years
Stroke recurrence rate and Stroke mortality
Sponsor's own description
The purpose of this study is to assess the efficacy and safety of Naoxintong Capsule in the secondary prevention of ischemic stroke by the multi-center, randomized,double-blind，placebo-controlled trial design project.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Naoxintong Capsule for Secondary Prevention of Ischemic Stroke: A Multicenter, Randomized, and Placebo-Controlled Trial.
Yu XF, Zhu XY, Yuan CX, Wu DH, et al · · 2022 · cited 11× · PMID 36251140 · DOI 10.1007/s11655-022-3586-8 -
Targeting ferroptosis with natural products in stroke: therapeutic mechanisms and translational opportunities.
Zheng Y, Tan X, Wang X, Mao R, et al · · 2025 · cited 2× · PMID 40510422 · DOI 10.3389/fphar.2025.1586345
Verify or expand the search:
- PubMed search for NCT02334969
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02334969 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiaofei Yu
- Last refreshed: 15 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02334969.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing